Impact of interleukin-6 on T cells in kidney transplant recipients.
Am J Transplant
; 22 Suppl 4: 18-27, 2022 12.
Article
em En
| MEDLINE
| ID: mdl-36453710
Interleukin-6 (IL-6), a multifunctional proinflammatory cytokine, plays a key role in T cell activation, survival, and differentiation. Acting as a switch that induces the differentiation of naïve T cells into Th17 cells and inhibits their development into regulatory T cells, IL-6 promotes rejection and abrogates tolerance. Therapies that target IL-6 signaling include antibodies to IL-6 and the IL-6 receptor and inhibitors of janus kinases; several of these therapeutics have demonstrated robust clinical efficacy in autoimmune and inflammatory diseases. Clinical trials of IL-6 inhibition in kidney transplantation have focused primarily on its effects on B cells, plasma cells, and HLA antibodies. In this review, we summarize the impact of IL-6 on T cells in experimental models of transplant and describe the effects of IL-6 inhibition on the T cell compartment in kidney transplant recipients.
Palavras-chave
clinical research/practice; cytokines/cytokine receptors; immunobiology; immunosuppressant-fusion proteins and monoclonal antibodies: T cell specific; immunosuppression/immune modulation; kidney transplantation/nephrology; lymphocyte biology: differentiation/maturation; rejection: T cell mediated (TCMR); tolerance: clinical; translational research/science
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Interleucina-6
/
Transplante de Rim
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article